IFG Advisory’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $191K | Sell |
878
-40,007
| -98% | -$8.87M | 0.55% | 29 |
|
|
2025
Q4 | $9.34M | Sell |
40,885
-337
| -0.8% | -$76.8K | 0.41% | 61 |
|
|
2025
Q3 | $9.54M | Buy |
41,222
+1,521
| +4% | +$310K | 0.43% | 57 |
|
|
2025
Q2 | $7.37M | Buy |
39,701
+1,297
| +3% | +$241K | 0.37% | 71 |
|
|
2025
Q1 | $8.05M | Buy |
38,404
+880
| +2% | +$171K | 0.45% | 54 |
|
|
2024
Q4 | $6.67M | Sell |
37,524
-54
| -0.1% | -$9.93K | 0.38% | 67 |
|
|
2024
Q3 | $7.42M | Buy |
37,578
+383
| +1% | +$71.5K | 0.47% | 48 |
|
|
2024
Q2 | $6.38M | Buy |
37,195
+1,001
| +3% | +$166K | 0.41% | 53 |
|
|
2024
Q1 | $6.59M | Sell |
36,194
-1,113
| -3% | -$192K | 0.49% | 44 |
|
|
2023
Q4 | $5.78M | Buy |
37,307
+13,022
| +54% | +$1.9M | 0.42% | 51 |
|
|
2023
Q3 | $3.62M | Buy |
24,285
+693
| +3% | +$102K | 0.3% | 82 |
|
|
2023
Q2 | $3.18M | Sell |
23,592
-934
| -4% | -$137K | 0.28% | 99 |
|
|
2023
Q1 | $3.91M | Buy |
24,526
+2,084
| +9% | +$319K | 0.37% | 66 |
|
|
2022
Q4 | $3.63M | Sell |
22,442
-6,042
| -21% | -$926K | 0.36% | 65 |
|
|
2022
Q3 | $3.82M | Buy |
28,484
+7,186
| +34% | +$1.03M | 0.35% | 65 |
|
|
2022
Q2 | $3.26M | Sell |
21,298
-3,749
| -15% | -$573K | 0.35% | 60 |
|
|
2022
Q1 | $4.06M | Sell |
25,047
-1,298
| -5% | -$189K | 0.41% | 53 |
|
|
2021
Q4 | $3.57M | Buy |
26,345
+2,445
| +10% | +$289K | 0.35% | 63 |
|
|
2021
Q3 | $2.58M | Buy |
23,900
+571
| +2% | +$65.2K | 0.28% | 83 |
|
|
2021
Q2 | $2.63M | Sell |
23,329
-3,503
| -13% | -$395K | 0.29% | 74 |
|
|
2021
Q1 | $2.9M | Buy |
26,832
+289
| +1% | +$30.9K | 0.36% | 67 |
|
|
2020
Q4 | $2.84M | Sell |
26,543
-8,569
| -24% | -$823K | 0.39% | 60 |
|
|
2020
Q3 | $3.08M | Buy |
35,112
+1,121
| +3% | +$106K | 0.5% | 43 |
|
|
2020
Q2 | $3.34M | Buy |
33,991
+4,343
| +15% | +$382K | 0.6% | 35 |
|
|
2020
Q1 | $2.26M | Buy |
29,648
+9,716
| +49% | +$828K | 0.5% | 48 |
|
|
2019
Q4 | $1.76M | Sell |
19,932
-341
| -2% | -$28.3K | 0.32% | 87 |
|
|
2019
Q3 | $1.53M | Buy |
20,273
+2,794
| +16% | +$192K | 0.3% | 94 |
|
|
2019
Q2 | $1.27M | Buy |
17,479
+328
| +2% | +$25.8K | 0.23% | 93 |
|
|
2019
Q1 | $1.38M | Buy |
17,151
+338
| +2% | +$27.7K | 0.26% | 85 |
|
|
2018
Q4 | $1.55M | Sell |
16,813
-16,060
| -49% | -$1.41M | 0.37% | 65 |
|
|
2018
Q3 | $3.11M | Buy |
32,873
+1,051
| +3% | +$99.7K | 0.58% | 32 |
|
|
2018
Q2 | $2.95M | Sell |
31,822
-13
| -0% | -$1.27K | 0.61% | 34 |
|
|
2018
Q1 | $3.01M | Sell |
31,835
-3,924
| -11% | -$431K | 0.67% | 30 |
|
|
2017
Q4 | $3.46M | Buy |
+35,759
| New | +$3.37M | 0.78% | 28 |
|
Other funds holding ABBV
VCM
VPM
IFG Advisory's ABBV Position: Q1 2026 in Review
IFG Advisory reduced its AbbVie (ABBV) stake by 98% in Q1 2026, selling an estimated $8.87M and leaving 878 shares worth $191K. The position accounts for 0.55% of the portfolio, ranked #29.
IFG Advisory first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $9.54M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- IFG Advisory held 878 shares of AbbVie worth $191K as of Q1 2026.
- IFG Advisory sold 40,007 AbbVie shares in Q1 2026, an estimated $8.87M.
- AbbVie made up 0.55% of IFG Advisory's portfolio in Q1 2026, its #29 holding.
- IFG Advisory first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- IFG Advisory's AbbVie position peaked at $9.54M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on IFG Advisory's 13F filing for Q1 2026, filed 12 May 2026.